2021 Women’s Venture Competition Announced Semi-Finalists!
The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee…
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and…
Making Cancer Patient Clinical Trial Recruitment & Engagement Easier
Are you struggling to increase clinical trial awareness, recruitment, and participant retention for your oncology drug trials? Building up an efficient pre-screening process becomes an urgent task for companies to connect with potential participants; keep them engaged through the trial…
Privo Technologies, Inc. to Present Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the Upcoming 2021 ASCO Annual Meeting
Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be "Tough on cancer, Easy on patients", announced today a poster presentation on the safety and efficacy of PRV111 in patients with early-stage Head and Neck Squamous Cell…
TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer
Closes $5 million Series A financing Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations Announces exclusive license of TellDx platform to Genetron Holdings Limited for China…
5 Questions with Dr. Sujuan Ba, Co-Founder & CEO of AIM-HI Accelerator Fund
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome 5 Questions with…
AIM-HI to Award $1 Million in Seed Funding to Female-Led Oncology Startup
The AIM-HI Accelerator Fund, a spin-off of the National Foundation for Cancer Research, aims to award $1 million to a female-led startup focused on meeting unmet needs across the oncology landscape. The organization is currently accepting applications for its 2021…
Applications Open for the 2021 AIM-HI Women’s Venture Competition!
Today is International Women’s Day. In honor of the occassion, the AIM-HI Accelerator Fund (AIM-HI) would like to highlight for you our venture philanthropy effort to provide critically needed seed funding to an underserved population: women scientist-entrepreneurs devoted to address…
Winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition Announced
Privo Technologies to Receive $900,000 of Investment Funding Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for…
Oncoheroes & SHEPHERD Therapeutics United Against Rare Cancers
On Childhood Cancer Day, SHEPHERD Therapeutics is joining forces with Oncoheroes Biosciences to bring new treatment options to children and adolescents with cancer. SHEPHERD is a Boston-based biotech company on a mission to change the way rare cancer is treated,…
Together, All of Our Actions Matter!
Every year, people around the world connect on a special day to support and remember the families and individuals affected by cancer. This day is called World Cancer Day, on February 4th. Over the past two decades, World Cancer Day…
Oncoheroes Biosciences Secures Additional Venture Philanthropy Investment
An additional venture philanthropy organization, the Catalytic Impact Foundation, which supports women’s health, brain health, children’s health, aging, and pediatric rare disease initiatives, is investing in AIM-HI Accelerator Fund portfolio company Oncoheroes Biosciences, further validating the start-up’s unique effort to…